Physician profile
Daniceli Martinez
NPI 1932631389
$1,225.62
in general payments reported to CMS, 2019-2025
18 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $23.40 · 2023: $309 · 2024: $258 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,202.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,202.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $238.81 | 2023-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $203.74 | 2022-2025 | Jynarque, Voyxact |
| Amgen INC. | $140.03 | 2023-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $103.50 | 2024-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $82.76 | 2025 | |
| Travere Therapeutics, INC. | $70.26 | 2023-2025 | Thiola |
| Nxstage Medical, INC. | $54.02 | 2025 | Nxstage Cartridge Express, Liberty Select Cycler, Nxstage System One |
| Fresenius USA Marketing, INC. | $53.76 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.92 | 2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $39.40 | 2023-2025 | Lupkynis |
| Vifor Pharma, INC. | $38.89 | 2023-2025 | Veltassa, Korsuva |
| Mallinckrodt Hospital Products INC. | $30.39 | 2024 | Terlivaz |
| Akebia Therapeutics INC | $28.72 | 2024 | Auryxia |
| Novartis Pharmaceuticals Corporation | $25.00 | 2025 | |
| Ani Pharmaceuticals, INC. | $20.00 | 2025 | Purified Cortrophin Gel |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $19.22 | 2024 | Oxlumo |
| Horizon Therapeutics Plc | $17.63 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $14.57 | 2023 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniceli Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.